OBI Pharma Inc (浩鼎) yesterday gained shareholders’ approval to issue new shares to fund its long-term development, clinical trial and diversification plans.
The biotech company received authorization to issue no more than 15 million new shares to raise between NT$3 billion and NT$4 billion (US$98.51 million and US$131.35 million) at its annual general meeting in Taipei.
In light of its depressed stock price, fundraising would take place over the next one or two years, the company said, adding that it is considering either a capital injection through a private placement or in conjunction with issuance of depositary receipts abroad.
The company said that while its cash balance of NT$4.2 billion is enough to sustain operations through 2020, additional funding would be required by then, when a number of projects are expected to progress to phase two clinical trials.
OBI Pharma shares yesterday dipped 0.32 percent to NT$157.50 in Taipei trading.
The stock was trading above NT$681 in 2016, before tumbling after phase two and three clinical trials showed no statistical significance in proving the effectiveness of its breast cancer drug OBI-222.
The company and its executives have since been embroiled in insider trading allegations, sending a shockwave through the nation’s biotechnology sector.
Following the setback, the company is set to begin enrolling patients for a redesigned phase three clinical trial for the drug in the US, president Amy Huang (黃秀美) said.
The redesigned clinical study expanded enrollment criteria, making it available to a larger number of patients who are in varying stages of treatment and disease progression, Huang said.
In particular, triple-negative breast cancer patients with a higher level of expression of Globo H, which the drug — renamed Adagloxad Simolenin — is designed to target and trigger an immune system response.
The enrollment process would take place over the next two years, followed by three years of primary endpoint study and another two years survival analysis, Huang said.
The company will continue to devote funds to diversify its development pipeline, chairman Michael Chang (張念慈) said.
It is collaborating with AP Biosciences (圓祥生技) on OBI-3424, a first-in-class DNA alkylating agent that targets cancers that overexpress the aldo-keto reductase 1C3 enzyme, which is part of efforts to explore new territories in immune checkpoint inhibitors and bi-specific antibodies, as well as liver cancer treatments, Chang said.
While the company has been vindicated after Taipei prosecutors in February dropped insider trading charges against former Academia Sinica president Wong Chi-huey (翁啟惠) and OBI Pharma executives, the judicial process has taken its toll on operations, Chang and Huang said.
Chang added that he is confident that he would receive a favorable court ruling on other charges in September.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained